Login to Your Account

Biogen sails to strong 2nd quarter on winds of SMA drug sales

By Michael Fitzhugh
Staff Writer

Tuesday, July 25, 2017

Strong sales of Biogen Inc.'s pricey spinal muscular atrophy drug, Spinraza, helped the company cruise past consensus estimates and hit record second-quarter sales on Tuesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription